These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 33346625)

  • 1. BRAIN HEALTH ASSESSMENT IN MACULAR DEGENERATION PATIENTS UNDERGOING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS (THE BHAM STUDY): An Interim Analysis.
    Ray SK; Manz SN
    Retina; 2021 Aug; 41(8):1748-1753. PubMed ID: 33346625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
    Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of monthly and fortnightly anti-VEGF treatments for age-related macular degeneration.
    Nunes RP; Hirai FE; Barroso LF; Badaró E; Novais E; Rodrigues EB; Maia M; Magalhães O; Farah ME
    Arq Bras Oftalmol; 2019; 82(3):225-232. PubMed ID: 30810619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EFFICACY OF ADJUVANT TOPICAL DORZOLAMIDE-TIMOLOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Lee JH; Lee SC; Byeon SH; Koh HJ; Kim SS; Lee CS
    Retina; 2019 Oct; 39(10):1953-1958. PubMed ID: 30161096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-Response Relationship between Intravitreal Injections and Retinal Nerve Fiber Layer Thinning in Age-Related Macular Degeneration.
    Wang L; Swaminathan SS; Yang J; Barikian A; Shi Y; Shen M; Jiang X; Feuer W; Gregori G; Rosenfeld PJ
    Ophthalmol Retina; 2021 Jul; 5(7):648-654. PubMed ID: 33045458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor.
    Soares RR; Mellen P; Garrigan H; Obeid A; Wibbelsman TD; Borkar D; Ho AC; Hsu J
    Ophthalmol Retina; 2020 Feb; 4(2):134-140. PubMed ID: 31540854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2014 Aug; 8(8):CD005139. PubMed ID: 25170575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.
    Jampol LM; Glassman AR; Bressler NM; Wells JA; Ayala AR;
    JAMA Ophthalmol; 2016 Dec; 134(12):. PubMed ID: 27711918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Altaweel M; Berinstein DM;
    JAMA Ophthalmol; 2018 Apr; 136(4):337-345. PubMed ID: 29476687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting vision gains with anti-VEGF therapy in neovascular age-related macular degeneration patients by using low-luminance vision.
    Frenkel RE; Shapiro H; Stoilov I
    Br J Ophthalmol; 2016 Aug; 100(8):1052-7. PubMed ID: 26541435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-VEGF therapy in symptomatic peripheral exudative hemorrhagic chorioretinopathy (PEHCR) involving the macula.
    Seibel I; Hager A; Duncker T; Riechardt AI; Nürnberg D; Klein JP; Rehak M; Joussen AM
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):653-9. PubMed ID: 26148802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world treatment outcomes of neovascular Age-related Macular Degeneration in the Netherlands.
    Verbraak FD; Ponsioen DL; Tigchelaar-Besling OAM; Nguyen V; Gillies MC; Barthelmes D; Klaver CCW
    Acta Ophthalmol; 2021 Sep; 99(6):e884-e892. PubMed ID: 33354933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE.
    Weiss M; Sim DA; Herold T; Schumann RG; Liegl R; Kern C; Kreutzer T; Schiefelbein J; Rottmann M; Priglinger S; KortUEm KU
    Retina; 2018 Dec; 38(12):2293-2300. PubMed ID: 29068914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of Anti-Vascular Endothelial Growth Factor Gene Therapy for Neovascular Age-Related Macular Degeneration.
    Berkowitz ST; Patel S
    Ophthalmol Retina; 2021 Apr; 5(4):357-364. PubMed ID: 32818623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different Clinical Courses on Long-Term Follow-Up of Age-Related Macular Degeneration Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Sagiv O; Zloto O; Moroz I; Moisseiev J
    Ophthalmologica; 2017; 238(4):217-225. PubMed ID: 28926846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal anti-vascular endothelial growth factor monotherapy for large submacular hemorrhage secondary to neovascular age-related macular degeneration.
    Kim HS; Cho HJ; Yoo SG; Kim JH; Han JI; Lee TG; Kim JW
    Eye (Lond); 2015 Sep; 29(9):1141-51. PubMed ID: 26272443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-VEGF-refractory exudative age-related macular degeneration: differential response according to features on optical coherence tomography.
    Shin JY; Woo SJ; Ahn J; Park KH
    Korean J Ophthalmol; 2013 Dec; 27(6):425-32. PubMed ID: 24311928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.